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Abstract: Background: Free fatty acid (FFA) metabolism can impact on metabolic conditions, such
as obesity and nonalcoholic fatty liver disease (NAFLD). This work studied the increase in total
FFA shown in NAFLD subjects to possibly characterize which fatty acids significantly accounted for
the whole increase. Methods: 21 patients with NAFLD were selected according to specified criteria.
The control group consisted of nine healthy subjects. All subjects underwent an oral standard fat load.
Triglycerides; cholesterol; FFA; glucose and insulin were measured every 2 h with the determination
of fatty acid composition of FFA. Results: higher serum FFA levels in NAFLD subjects are mainly due
to levels of oleic, palmitic and linoleic acids at different times. Significant increases were shown for
docosahexaenoic acid, linolenic acid, eicosatrienoic acid, and arachidonic acid, although this was just
on one occasion. In the postprandial phase, homeostatic model assessment HOMA index positively
correlated with theω3/ω6 ratio in NAFLD patients. Conclusions: the higher serum levels of FFA in
NAFLD subjects are mainly due to levels of oleic and palmitic acids which are the most abundant
circulating free fatty acids. This is almost exactly corresponded with significant increases in linoleic
acid. An imbalance in the n-3/n-6 fatty acids ratio could modulate postprandial responses with more
pronounced effects in insulin-resistant subjects, such as NAFLD patients.
Keywords: nonalcoholic fatty liver disease; free fatty acids; insulin resistance
1. Introduction
Free fatty acid (FFA) metabolism can widely impact on metabolic health. Several metabolic
conditions, such as obesity, insulin resistance, type 2 diabetes, and non-alcoholic steatohepatitis, are
associated with increased total concentrations of serum free fatty acids [1,2]. Nonalcoholic fatty
liver disease (NAFLD) encompasses a spectrum of conditions characterized histologically by hepatic
steatosis in individuals without significant alcohol consumption and negative viral, congenital and
autoimmune liver disease markers. Hepatic lipid accumulation results from an imbalance between
lipid availability and lipid disposal [3,4]. In this context, the composition of serum FFA has been poorly
studied so far, especially in the postprandial state [5]. High levels of saturated fatty acids (SFA) were
reported to increase coronary risk [6,7].
The liver is the main organ regulating fatty acid metabolism. Several sources supply the liver
with a continuous flux of fatty acids [8]. In particular, in the fasting state free fatty acids coming from
the lipolysis in adipose tissue fuel the liver. In the fed state, there are two major forms of dietary
fatty acids which are available to the liver. In esterified forms, fatty acids are carried to the liver by
triacylglycerol–rich chylomicron remnant particles and, as FFA, they stem from the so called spillover
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mechanism: in the spillover mechanism, FFA are released from chylomicron triacylglycerol by the
activity of lipoprotein lipase (LPL, n. EC 3.1.1.34) in peripheral tissues, mainly adipose tissue [9].
Moreover, hepatic “de novo” lipogenesis (DNL) from non-lipid precursor increases the content of fatty
acid in the liver.
After SFA exposure, in vitro experiments had shown that different cell types were induced
to synthetize proinflammatory cytokines; they were more prone to apoptosis and had impaired
insulin signaling [10,11]. By contrast, the exposure of monounsaturated fatty acids does not seem to
trigger apoptosis [12]. Different signaling mechanisms were suggested in order to explain how SFA
triggers apoptosis in hepatic cells. Endoplasmic reticulum (ER) stress, mitochondrial dysfunction, Jun
N-terminal kinase (JNK) signaling and lipotoxicity are the main molecular mechanisms through which
fatty acids exert their deleterious effects on the human metabolism. Wistar rats fed with a diet high
in saturated fats showed liver damage and hepatic ER stress [13]. ER stress was due to a decreased
fluidity of the lipid bilayer for abnormal incorporation of saturated phospholipids [14]. Excess of
unesterified SFA is assembled into saturated phospholipid species leading to stiffening of cellular
membranes [15]. Dysregulation of mitochondrial metabolism is due to an imbalance between the
glycolytic fluxes and tricarboxylic acid (TCA) cycle since palmitate inhibits glycolytic flux and up
regulates TCA cycle and anaplerotic fluxes [16]. The altered mitochondrial metabolism generates an
elevated level of reacting oxygen species (ROS) stimulating apoptosis. An accelerated mitochondrial
metabolism was observed in NAFLD patients [17]. Additionally, under either ER stress or oxidative
stress, molecular signaling arises from JNK activation. Palmitate-induced JNK phosphorylation can be
reversed in hepatic cells with administration of antioxidants [18]. SFA shows also a high degree of
lipotoxicity. For instance, ceramide synthesis was associated with apoptosis in a hemopoietic precursor
cell line [19] and with insulin resistance [20]. In this context, circulating FFAs, which should provide the
substrate for triacylglycerol formation, may turn out to be cytotoxic in certain circumstances, such as
under insulin resistance. NAFLD is characterized by elevated serum concentration of FFAs, hepatocyte
apoptosis, progressive inflammation and fibrosis. In this work, we investigated the composition of
circulating FFA in normal and NAFLD subjects during fasting and after a standard oral lipid load.
Cultured hepatocytes incubated with FFA of various lengths demonstrated an inverse correlation
between FA chain lengths and NAFLD induction [21].
The aim of our work was to study in depth the well-known significant increase in total free fatty
acids shown in NAFLD subjects, and to possibly characterize which fatty acids significantly accounted
for the whole increase, with specific regard to their classification (saturated, n-3, n-6 polyunsaturated
fatty acids).
2. Results
Main basal features of the patients and control subjects are reported in Table 1. After oral fat load
in NAFLD patients, triglycerides reached their maximum peak after around 4 h and they circulated at
higher levels than in control subjects. The differences were significant at all times (Figure 1a). The trend
of FFA over a 4 h period after the oral fat load is different between NAFLD patients and control subjects
(Figure 1b). NAFLD patients showed higher FFA levels than control subjects from baseline through
the end of the oral fat load with significant differences at times 60, 150, 180 and 210 min.
Table 1. Subjects baseline physical characteristics and fasting blood measurements.
Parameters Control Group (n = 9) NAFLD Group (n = 21) p
Age (year) 27 ˘ 2 40 ˘ 9 0.001
BMI (kg/m2) 21 ˘ 2 28 ˘ 4 0.002
Systolic blood pressure (mmHg) 119 ˘ 4 125 ˘ 8 0.049
Waist (cm) 73 ˘ 6 94 ˘ 8 0.000001
Diastolic blood pressure (mmHg) 80 ˘ 0 82 ˘ 9 0.615
Glucose (mg/dL) 91 ˘ 5 98 ˘ 11 0.097
Triglycerides (mg/dL) 59 ˘ 19 100 ˘ 49 0.021
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Table 1. Cont.
Parameters Control Group (n = 9) NAFLD Group (n = 21) p
Cholesterol (mg/dL) 168 ˘ 27 182 ˘ 34 0.306
HDL-Chol (mg/dL) 54 ˘ 13 42 ˘ 8 0.007
HDL2-Chol (mg/dL) 20 ˘ 8 12 ˘ 4 0.003
HDL3-Chol (mg/dL) 34.22 ˘ 5 30 ˘ 5 0.072
LDL-Chol (mg/dL) 107 ˘ 27 125 ˘ 29 0.139
FFA (mmol/L) 0.73 ˘ 0.41 1.07 ˘ 0.59 0.131
sdLDL (mg/dL) 21 ˘ 11 31 ˘ 18 0.127
c-Peptide (pM/mL) 0.54 ˘ 0.13 0.92 ˘ 0.35 0.004
Insulin (µU/mL) 6.28 ˘ 1.99 12.7 ˘ 7.68 0.021
AST (U/L) 20 ˘ 4 33 ˘ 10 0.002
ALT (U/L) 16 ˘ 4 64 ˘ 30 0.001
GGT (U/L) 14 ˘ 12 80 ˘ 74 0.021
ALP (U/L) 51 ˘ 21 75 ˘ 23 0.016
HOMA-IR 1.42 ˘ 0.49 3.16 ˘ 2.13 0.024
QUICKI index 0.367 ˘ 0.02 0.333 ˘ 0.03 0.008
Abbreviations: HDL-Chol, High density lipoprotein-Cholesterol; HDL2-Chol, High density
lipoprotein 2-Cholesterol; HDL3-Chol, High density lipoprotein 3-Cholesterol; LDL-Chol, Low density
lipoprotein-Cholesterol; FFA, free fatty acids; sdLDL, small dense low-density lipoproteins; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase;
HOMA-IR, homeostatic model assessment-insulin resistance; QUICKI index, quantitative insulin sensitivity
check index.
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Figure 1. Time courses for total plasma triglycerides (box a) and free fatty acids (box b) 
concentrations during the oral fat meal in control (filled diamonds) and nonalcoholic fatty liver 
disease (NAFLD) (filled squares) subjects. Values are expressed as mean ±SEM. * p < 0.05, ** p < 0.01. 
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Figure 1. Time courses for total plasma triglycerides (box a) and free fatty acids (box b) concentrations
during the oral fat meal in control (filled diamonds) and nonalcoholic fatty liver disease (NAFLD)
(filled squares) subjects. Values are expressed as mean ˘SEM. * p < 0.05, ** p < 0.01.
Int. J. Mol. Sci. 2016, 17, 479 4 of 15
The trend of glycemia is dotted in Figure 2a and it shows a slight decrease from baseline to
90 min both in NAFLD and control group and then a constant course up to 240 min with a statistically
significant difference at 210 min. Insulin curve showed in NAFLD patients a major peak at 30 min and
higher levels than in control subjects. At all times, except at 180 min, there were statistically significant
differences (Figure 2b).
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Figure 2. Time courses for glucose (box a) and insulin (box b) concentrations during the oral fat meal
in control (filled diamonds) and NAFLD (filled squares) subjects. Values are expressed as mean ˘ SEM.
* p < 0.05, ** p < 0.01.
Fatty acid values are given as percentage contents (mmol/100 mmol total fatty acids) since the
between-individual variations in the molar concentration of total serum FFA is very high [22]. Figure 3
shows the trends of saturated fatty acids lauric (12:0) (a), myristic (14:0) (b) and stearic (18:0) (STA) (c)
which did not present significant statistical differences between the two groups.
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Figure 3. Change in plasma levels of saturated lauric (box a), myristic (box b) and stearic (box c) acid
during the oral fat meal in control (filled diamonds) and NAFLD (filled squares) subjects. Values are
expressed as mean ˘ SEM.
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Figure 4 shows the trends of oleic acid (18:1n-9) (OLA) eluted with palmitic acid (16:0) (PAL),
a saturated fatty acid. Oleic and palmitic acids amounts reached their peak at 180 min in NAFLD
patients and were statistically higher in NAFLD patients than in control subjects at times 60, 150, and
210 min.
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The monounsaturated palmitoleic acid (16:1n-7) fell from baseline to 90 min in NAFLD subjects
and from baseline to 150 min in control subjects. Then, in both group palmitoleic acids rose
progressively up until the end of the test. No significant differences were observed between NAFLD
and control subjects (Figure 5a).
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Linoleic acid (18:2n-6) (LNA) throughout the fat load showed significant differences at times 60,
150, 180, 210, and 240 min between NAFLD and control subjects (Figure 5b).
Eicosatrienoic acid (20:3n-9) in NAFLD patients had higher levels than in control subjects with
significant differences from 150 min to the end of the fat oral test (Figure 5c).
Docosahexaenoic (22:6n-3) (DHA) a d linolenic acids (18:3n-3) (ALA), two polyunsaturated fatty
acids, are significantly increased in NAFLD patients at 150 and 180 min, compared to control subjects
(Figure 5d).
Arach donic acid (20:4n-6) (ARA) showed an almost flat trend in both NAFLD and control group
with a significa t differenc at 60 min (Figure 5e).
The n-3/n-6 ratio measured at every time is not statistically different between control and NAFLD
groups. HOMA-IR was higher in NAFLD subjects compared to the control subjects (3.16 ˘ 2.13 vs.
1.42 ˘ 0.49, p = 0.024). HOMA index positively correlated with the n-3/n-6 ratio at time 210 and
240 min in NAFLD patients (r = 0.55, p = 0.0122 and r = 0.47, p = 0.035, respectively) (Figure 6a,b).
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Figure 6. Correlation between homeostatic model assessment HOMA index and n-3/n-6 ratio at time
210 min in NAFLD patients (box 6a); correlation between HOMA index and n-3/n-6 ratio at time
240 min in NAFLD patients (box 6b); Figure 6a: PUFA n-3/n-6 at 210 min vs. HOMA in NAFLD;
r = 0.54883, PUFA n-3/n-6 at 210 in; Figure 6b: PUFA n-3/n-6 at 240 min vs. HOMA in NAFLD;
r = 0.47351, PUFA n-3/n-6 at 240 min.
3. Discussion
Free fatty acids derived from the diet can directly enter the circulation through spillover into
the plasma FFA pool [23]. Other potential sources of fats causing fatty liver include adipose tissue
from where non-esterified fatty acids flow to the liver, de novo lipogenesis and through the uptake of
intestinally derived chylomicron remnants [24]. After a fatty meal, the FFA profile mirrors that of the
meal [25]. We performed an abbreviated 4- our postprandial fat load which was a valid surrogate for
longer oral fat loads [26].
In the postprandial hase, the high in ulin emia and triglyc ridemia observed in NAFLD p tients
confirms the insulin resistance state in these subjects [27]. Insulin does not suppress hormone-sensitive
lipase in adipose tissue as in healthy subjects; therefore, in the postprandial phase, adipocyte-derived
FFA mix with fatty acids coming from the diet and they can reach the liver.
The peak of triglycerides starts at around 4 h after the fatty meal in NAFLD subjects whilst
in control subjects the peak is reached earlier. That means a delayed clearance of triglyceride-rich
lipoproteins in NAFLD patients [28].
FFA levels are high in NAFLD patients compared to normal subjects with a trend similar to that
of oleic and palmitic acid l vels (Figures 1b and 4). This study shows hat the high r serum levels of
free fatty acid i NAFLD subjects are mainly due to levels of oleic (n9) and palmitic a ids (repo ted as
unique value in the data presented) which are the most abundant circulating free fatty acids (60, 150,
and 210 min after the oral fat load) (Figures 1b and 4). Almost at the same time, linoleic acid (n6) levels
increase significantly (60, 150, 180, 210, 240 min) (Figure 5b). Significant increases were also shown for
docosahexaenoic acid (n3), linolenic acid (n-3) (Figure 5d), eicosatrienoic acid (n-9) (Figure 5c), and
arachidonic acid (n6) (Figure 5e), although just on one occasion.
High levels of oleic and pal itic acids have molecular implications: oleic acid is the preferred
substrate for the synthesis of triglycerides, and cholesteryl esters [29]. Palmitic acid is the substrate for
isofo ms 1 and 6 of fatty acid elongase (El v-1 and Elov-6) which re converted into stearic ci [30].
Stearic acid is rapidly converted to oleic acid by the enzyme stearoyl-CoA 9-desaturase (SCD, No. EC
1.14.19.1) in mammalian cells [31]. A single double bond between carbon 9 and 10 is introduced in
the chain of palmitic and stearic acids to be converted to palmitoleate and oleate, respectively [24].
The cellular ratio of oleic and stearic acids can affect membrane fluidity and signal transduction
leading to an altered composition of membrane phospholipids, triglycerides and cholesterol esters [32].
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Subjects exhibiting a hypertriglyceridemic response to a low-fat, high-carbohydrate diet show an
increase in the oleic to stearic acids ratio [33].
Eicosatrienoic acid is significantly increased towards the end of the test in NAFLD subjects
(Figure 5c). This increase is unlikely to be due to the meal composition since eicosatrienoic acid is
of a negligible amount in dairy cream. Rather, eicosatrienoic acid might be derived from oleic acid
metabolism [34].
Linolenic and DHA acids are two PUFA n-3 that coelute in our HPLC method. They significantly
increase in NAFLD subjects at time 150 and 180 min. Humans have the ability to metabolize linolenic
acids to their longer chain DHA even if this conversion is less than 1% in adults [35]. Further studies
are needed to verify its physiological functions. The competition between n-3 and n6 fatty acids
for the same enzymes and transport systems might explain why linoleic acid showed a flat trend
throughout the test, even though they were found at higher concentrations in NAFLD patients than in
control subjects.
The n-3/n-6 ratio measured every 30 min is not statistically different even if the ratio is slightly
higher in control subjects than in NAFLD patients. When the n-3/n-6 ratio was correlated with
HOMA-IR, it was found that HOMA index positively correlated with the n-3/n-6 ratio at times 210
and 240 min only in NAFLD patients (Figure 6a,b). Therefore, subjects who have a basal insulin
resistance have higher n-3/n-6 ratio towards the end of the test as if higher n-3 fatty acids could worsen
the clearance of triglycerides in NAFLD subjects. On the contrary, in healthy subjects with optimal
insulin sensitivity, n-3 fatty acids could have beneficial influence on the lipid clearance. Our data seem
to be in contrast with previous studies suggesting that increasing consumption of n-3 PUFA could
improve lipid metabolism both in the fasting and postprandial states [36] even if modifying the n-3/n-6
polyunsaturated fatty acid ratio of a high-saturated fat challenge did not acutely change postprandial
triglyceride response in men with metabolic syndrome [37]. It is likely for n-3 PUFA to need more
than 8 h to exert beneficial effects in subjects with an impaired lipid metabolism [35]. Amount and
type of dietary fatty acids can influence postprandial response [38]. Therefore, an imbalance in the
n-3/n-6 fatty acids ratio could modulate postprandial response with more pronounced effects in
insulin resistant subjects, such as NAFLD patients.
This preliminary study has some limitations due to the reduced number of control subjects
available for the study which prevents us from matching by age, sex, BMI and also by physical activity
on daily bases. The patients enrolled should be matched for a de novo clinical investigation to expand
these preliminary results.
4. Experimental Section
4.1. Subjects
Twenty-one patients (ethics committee of University Hospital San Giovanni Battista of Torino,
00096648, 30 December 2009) with NAFLD (mean age ˘ SD, 40 ˘ 9 years, BMI 27.5 ˘ 3.9 kg/m2)
attending our Liver Unit were selected according to the following criteria: persistently (at least
12 months) elevated aspartate aminotransferases (AST) and alanine aminotransferases (ALT) in
the absence of significant alcohol consumption (defined as <20 in men and <10 g/day in women);
ultrasonographic presence of bright liver without any other liver or biliary tract disease. At ultrasounds,
the diagnosis of NAFLD was based on four parameters: diffuse hyperechoic echotexture (“bright
liver”), increased liver echotexture compared with the kidneys, vascular blurring and deep attenuation.
Control subjects had a normal ultrasound liver scan.
Conditions known to be associated with fatty liver were ruled out by the following exclusion
criteria: a Body Mass Index (BMI) ě35 kg/m2; positive serum markers of viral, autoimmune or
celiac disease; abnormal copper metabolism or thyroid function indices; a diagnosis of diabetes
mellitus based on plasma glucose ě126 mg/dL in fasting conditions or ě200 mg/dL at +2 h on
a standard oral glucose tolerance test, serum total cholesterol ě220 mg/dL, serum triglycerides
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ě160 mg/dL. The patients did not take drugs known to be steatogenic or to affect glucose metabolism
and were not exposed to occupational hepatotoxins. The control group consisted of 9 healthy subjects
(mean age ˘ SD, 27 ˘ 2 years, BMI 21.2 ˘ 1.6 kg/m2) with normal liver enzymes and abdomen
ultrasound scan (see Table 1).
4.2. Oral Fat Load
NAFLD patients and controls underwent a standard oral fat load to investigate the metabolism of
triglyceride-rich lipoproteins and FFAs. The standard fat load consisted of a mixture of dairy cream
(38% fat) and egg yolk for a total energy content of 745.22 Kcal. The fat meal was composed of 79.96 g
fats, whose 54.32 g was of saturated fatty acids, 21.80 g of monounsaturated fatty acids, 2.82 g of
polyunsaturated fatty acids, and 0.45 g of cholesterol. The Table 2 shows the amounts of the most
represented fatty acids in the fat meal given to every participant.
Table 2. Fatty acid composition of lipid mixture prepared for the oral fat load.
Fatty Acids 200 g Dairy Cream (38% fat) NO. 1 Egg Yolk Total Fat Load
C12:0 (g) 3.02
C14:0 (g) 9.18 0.013
C16:0 (g) 21.40 1.020
C18:0 (g) 7.54 0.630
Total SFA (g) 52.75 1.67 54.32
C18:1 (g) 18.00 1.30
Total MUFA (g) 20.48 1.33 21.81
C18:2 (g) 1.52 0.650
C18:3 (g) 0.20 0.019
C20:4 (g) 0.120
Total PUFA (g) 2.07 0.74 2.82
Total fat (g) 75.30 4.66 79.96
Cholesterol (mg) 228.00 213.92 441.92
Proteins (g) 1.60 2.53 4.12
Carbohydrates (g) 2.28 2.28
Kcal 693.20 52.02 745.22
The fat load was consumed during a period of 5 min; subjects kept fasting and strenuous
activity was forbidden during the test, since exercise can reduce postprandial lipemia. A catheter
(Venflon Viggo AB, Helsingborg, Sweden) inserted in the antecubital vein and kept patent during
the test was used to draw blood samples at baseline and every 30 min for 4 h for biochemical
determinations. Blood samples were collected in tubes containing EDTA as anticoagulant and plasma
was immediately frozen. All subjects provided their informed consent for the study, which was
conducted in conformance with the Helsinki Declaration.
4.3. Biochemical Analyses
Serum glucose was measured by the glucose oxidase method (Sentinel, Milan, Italy) with an
intra-assay variation coefficient of 1.07% and an inter-assay variation coefficient of 2.33%.
Triglycerides (Tg) and cholesterol (Chol) were assayed by enzymatic colorimetric assays (Sentinel,
Milan, Italy) with an intra-assay variation coefficient of 2.99% and an inter-assay variation coefficient of
3.46% for triglycerides and with an intra-assay variation coefficient of 2.2% and an inter-assay variation
coefficient of 3.38% for cholesterol.
HDL-Chol was determined by enzymatic colorimetric assay after precipitation of LDL and VLDL
fractions using heparin-MnCl2 solution and centrifugation at 4 ˝C [39], and it had an intra-assay
variation coefficient of 2.5% and an inter-assay variation coefficient of 4.1%.
HDL2- and HDL3-Chol levels were determined according to Gidez et al. [40]: HDL2 and HDL3
lipoproteins were separated after precipitation of Apo B-containing lipoproteins with heparin-MnCl2,
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and HDL2 particles were further precipitated with dextran sulphate. HDL3-Chol was determined in
the supernatant. HDL2-Chol was obtained by subtracting HDL3-Chol from total HDL-Chol.
LDL-Chol was measured with a standardized homogeneous enzymatic colorimetric method in
order to avoid triglycerides effects on LDL-Chol determination (Sentinel, Milan, Italy).
QUICKI was calculated from fasting glucose and insulin values as previously reported [41].
HOMA was calculated using units of millimoles per liter for glucose and microunits per milliliter
for insulin [42].
The determination of fatty acid composition of free fatty acids was performed by high performance
liquid chromatography (HPLC) coupled with a fluorescence detector [43]. This procedure enables
the analyses of the content and profile of free fatty acids in total lipids extract. For free fatty acids’
analyses, we prepared an acidified sample mixture containing a small volume of serum and 10% acetic
acid. The mixture was applied onto C18 minicolumn and the column was washed with 10% acetic
acid. The fatty acids were eluted with ethyl ether. The ether phase was evaporated and dried under
vacuum at room temperature; the residue was dissolved into the derivatization solution containing the
labeling fluorescent compound. A very small volume was injected in a HPLC reverse phase column
and the free fatty acids profile was obtained within 45 min. Concentrations of each free fatty acid were
obtained from a calibration curve made of 10 fatty acids run at 5 levels.
4.4. Statistical Analysis
Data were expressed as means ˘ SD. Between-group comparisons (NAFLD vs. control groups)
were performed by using independent “t-test”. To assess correlations between data, the Pearson
correlation coefficient was calculated. Differences were considered statistically significant at p < 0.05.
5. Conclusions
The postprandial lipid metabolism in NAFLD subjects is very complex and partially understood.
Although the excessive flow of FFA from adipose tissue, especially from abdominal obesity (Table 1),
to the liver is considered to be the most important trigger of the NAFLD, little is known about the type
of free fatty acids reaching the liver. In literature, there are few data dealing with levels of different
circulating free fatty acids, but these data were usually measured only at baseline and come from small
groups of subjects [5]; however, they confirmed a significant increase of oleic, palmitoleic and palmitic
acids at baseline.
Taking into account the results coming out of this study, it would seem advisable for NAFLD
subjects to not only follow a saturated fatty acid-free diet, but also be careful not to consume large
amounts of n-3/n-6 PUFA. Obviously, these preliminary data should be further confirmed with larger
clinical trials which could help to develop tailored nutritional interventions aimed to improving lipid
metabolism in NAFLD subjects with the use of dynamic tests.
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